Eli Lilly and Co. and Biosite, Inc. have signed an agreement to collaborate on a clinical trial employing a therapy strategy for Lilly’s severe sepsis drug, Xigris. The trial, RESPOND (Research Evaluating Serial Protein C levels in severe sepsis patients ON Drotrecogin alfa), will investigate the use of a multipurpose biomarker, Protein C, to be used in connection with the administration of Xigris. Under the terms of the agreement, Biosite will develop a rapid, point-of-care diagnosti...